PatientsControls and Multiple Sclerosis Peripheral Blood Mononuclear Cells from Levels in γ Proliferator-Activated Receptor Pioglitazone Treatment Regulate Peroxisome Proinflammatory Stimulation and

The peroxisome proliferator-activated receptor (cid:1) (PPAR- (cid:1) ) belongs to a receptor superfamily of ligand-activated transcription factors involved in the regulation of metabolism and inflammation. Oral administration of PPAR- (cid:1) agonists ameliorates the clinical course and histopathological features in experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis (MS), and PPAR- (cid:1) agonist treatment of PBMCs from MS patients suppresses PHA-induced cell proliferation and cytokine secretion. These effects are pronounced when cells are preincubated with the PPAR- (cid:1) agonists and reexposed at the time of stimulation, indicating a sensitizing effect. To characterize the mechanisms underlying this sensitizing effect, we analyzed PPAR- (cid:1) expression in PMBCs of MS patients and healthy controls. Surprisingly, MS patients exhibited decreased PPAR- (cid:1) levels compared with controls. PHA stimulation of PBMCs from healthy controls resulted in a significant loss of PPAR- (cid:1) , which was prevented by in vitro preincubation of the cells or in vivo by long-term oral medication with the PPAR- (cid:1) agonist pioglitazone. Differences in PPAR- (cid:1) expression were accompanied by changes in PPAR- (cid:1) DNA-binding activity, as preincubation with pioglitazone increased DNA binding of PPAR- (cid:1) . Additionally, preincubation decreased NF- (cid:2) B DNA-binding activity to control levels, whereas the inhibitory protein I (cid:2) B (cid:3) was increased. In MS patients, pioglitazone-induced increase in PPAR- (cid:1) DNA-binding activity and decrease in NF- (cid:2) B DNA-binding activity was only observed in the absence of an acute MS relapse. These results suggest that the sensitizing effect observed in the preincubation experiments is mediated by prevention of inflammation-induced suppression of PPAR- (cid:1) expression with consecutive increase in PPAR- (cid:1) DNA-binding activity. The Journal of Immunology, 2005, 175: 4948–4955.

[1]  A. Sugawara,et al.  Transcription Suppression of Peroxisome Proliferator-Activated Receptor γ2 Gene Expression by Tumor Necrosis Factor α via an Inhibition of CCAAT/ Enhancer-binding Protein δ during the Early Stage of Adipocyte Differentiation , 2004 .

[2]  C. Glass,et al.  Repression of IFN-γ Expression by Peroxisome Proliferator-Activated Receptor γ1 , 2004, The Journal of Immunology.

[3]  D. Feinstein,et al.  Anti‐inflammatory and antiproliferative actions of PPAR‐γ agonists on T lymphocytes derived from MS patients , 2004, Journal of leukocyte biology.

[4]  S. Kotterba,et al.  Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria , 2003, Acta neurologica Scandinavica.

[5]  T. Klockgether,et al.  Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARγ) in murine primary astrocytes and neurons , 2003, Journal of neurochemistry.

[6]  J. Schlezinger,et al.  Peroxisome Proliferator-Activated Receptor γ-Mediated NF-κB Activation and Apoptosis in Pre-B Cells1 , 2002, The Journal of Immunology.

[7]  B. Brüne,et al.  Activation of Peroxisome Proliferator-Activated Receptor γ by Nitric Oxide in Monocytes/Macrophages Down-Regulates p47phox and Attenuates the Respiratory Burst1 , 2002, The Journal of Immunology.

[8]  C. Brosnan,et al.  Peroxisome proliferator‐activated receptor‐γ agonists prevent experimental autoimmune encephalomyelitis , 2002 .

[9]  P. Libby,et al.  PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis , 2002, Circulation research.

[10]  H. Hartung,et al.  New concepts in the immunopathogenesis of multiple sclerosis , 2002, Nature Reviews Neuroscience.

[11]  J. Bright,et al.  Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation , 2002, Genes and Immunity.

[12]  A. Lovett-racke,et al.  Peroxisome Proliferator-Activated Receptor-γ Agonist 15-Deoxy-Δ12,1412,14-Prostaglandin J2 Ameliorates Experimental Autoimmune Encephalomyelitis1 , 2002, The Journal of Immunology.

[13]  Y. Terauchi,et al.  Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. , 2001, The Journal of clinical investigation.

[14]  M. Ato,et al.  Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ , 2001, Journal of Neuroimmunology.

[15]  P. Anderson,et al.  Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. , 2001, International immunopharmacology.

[16]  J. Stephens,et al.  Interferon-γ-induced Regulation of Peroxisome Proliferator-activated Receptor γ and STATs in Adipocytes* , 2001, The Journal of Biological Chemistry.

[17]  S. Baranzini,et al.  Transcriptional Analysis of Multiple Sclerosis Brain Lesions Reveals a Complex Pattern of Cytokine Expression1 , 2000, The Journal of Immunology.

[18]  C. Polman,et al.  Contrasting responses to interferon β‐1b treatment in relapsing‐remitting multiple sclerosis: Does baseline interleukin‐12p35 messenger RNA predict the efficacy of treatment? , 2000, Annals of neurology.

[19]  G. Levi,et al.  Role of the peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) and its natural ligand 15‐deoxy‐Δ12,14‐prostaglandin J2 in the regulation of microglial functions , 2000 .

[20]  Taosheng Chen,et al.  Activation of Human T Lymphocytes Is Inhibited by Peroxisome Proliferator-activated Receptor γ (PPARγ) Agonists , 2000, The Journal of Biological Chemistry.

[21]  T. Hla,et al.  The Nuclear Receptor PPARγ and Immunoregulation: PPARγ Mediates Inhibition of Helper T Cell Responses1 , 2000, The Journal of Immunology.

[22]  G. Moretto,et al.  Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. , 1999, The American journal of pathology.

[23]  J. Uhm,et al.  Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon β‐1b therapy , 1999, Annals of neurology.

[24]  B. Hilliard,et al.  Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation and differentiation of autoreactive T cells. , 1999, Journal of immunology.

[25]  A. Fontana,et al.  Role of IκBα and IκBβ in the biphasic nuclear translocation of NF‐κB in TNFα‐stimulated astrocytes and in neuroblastoma cells , 1999 .

[26]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[27]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[28]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[29]  R. Hohlfeld,et al.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.

[30]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[31]  J. Lehmann,et al.  Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. , 1996, Molecular pharmacology.

[32]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[33]  F. Zipp,et al.  The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis , 1995, Neurology.

[34]  C. Raine,et al.  The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.

[35]  A. Broocks,et al.  Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity , 1995, Annals of neurology.

[36]  D. Fitzgerald,et al.  Experimental Autoimmune Encephalomyelitis , 2008 .

[37]  J. Schlezinger,et al.  Peroxisome Proliferator-Activated Receptor -Mediated NF- B Activation and Apoptosis in Pre-B Cells , 2002 .

[38]  J. Christman,et al.  The Role of Nuclear Factor-k B in Cytokine Gene Regulation , 1998 .

[39]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.